Real-time Estimate
Cboe BZX
11:17:05 2024-05-28 am EDT
|
5-day change
|
1st Jan Change
|
10.12
USD
|
+0.15%
|
|
-4.64%
|
-10.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
62.47
|
231.6
|
182
|
113.8
|
202.9
|
200
|
-
|
-
|
Enterprise Value (EV)
1 |
62.47
|
231.6
|
182
|
113.8
|
202.9
|
200
|
200
|
200
|
P/E ratio
|
-7.73
x
|
-17
x
|
-5.43
x
|
-4.17
x
|
-6.74
x
|
-3.76
x
|
-3.96
x
|
-4.12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
21,206
x
|
1,006
x
|
304
x
|
1,309
x
|
7,143
x
|
6,897
x
|
6,780
x
|
EV / Revenue
|
-
|
21,206
x
|
1,006
x
|
304
x
|
1,309
x
|
7,143
x
|
6,897
x
|
6,780
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-4,122,349
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,771
|
13,448
|
17,843
|
17,946
|
18,022
|
19,782
|
-
|
-
|
Reference price
2 |
5.800
|
17.22
|
10.20
|
6.340
|
11.26
|
10.11
|
10.11
|
10.11
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0109
|
0.181
|
0.374
|
0.155
|
0.028
|
0.029
|
0.0295
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.756
|
-12.23
|
-29.15
|
-25.95
|
-29.74
|
-49.82
|
-50.99
|
-52.09
|
Operating Margin
|
-
|
-111,975.09%
|
-16,106.63%
|
-6,938.77%
|
-19,187.74%
|
-177,934.54%
|
-175,843.1%
|
-176,572.88%
|
Earnings before Tax (EBT)
1 |
-7.678
|
-12.1
|
-30.34
|
-27.3
|
-30.01
|
-49.76
|
-51.01
|
-52.1
|
Net income
1 |
-7.678
|
-12.1
|
-30.34
|
-27.3
|
-30.01
|
-49.76
|
-51.01
|
-52.1
|
Net margin
|
-
|
-110,798.17%
|
-16,762.43%
|
-7,299.2%
|
-19,360%
|
-177,732.14%
|
-175,898.28%
|
-176,627.12%
|
EPS
2 |
-0.7500
|
-1.010
|
-1.880
|
-1.520
|
-1.670
|
-2.690
|
-2.555
|
-2.455
|
Free Cash Flow
|
-
|
-
|
-44.15
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-24,392.27%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.163
|
0.163
|
0.016
|
0.098
|
0.097
|
-
|
0.046
|
0.043
|
0.028
|
0.014
|
0.00467
|
0.00467
|
0.00467
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.03
|
-6.478
|
-6.388
|
-7.443
|
-5.642
|
-
|
-6.411
|
-8.528
|
-8.379
|
-11.02
|
-11.91
|
-12.92
|
-13.97
|
Operating Margin
|
-5,539.88%
|
-3,974.23%
|
-39,925%
|
-7,594.9%
|
-5,816.49%
|
-
|
-13,936.96%
|
-19,832.56%
|
-29,925%
|
-78,692.86%
|
-255,124.84%
|
-276,609.64%
|
-299,200.64%
|
Earnings before Tax (EBT)
1 |
-9.671
|
-6.903
|
-6.838
|
-7.725
|
-5.833
|
-
|
-6.501
|
-8.563
|
-8.408
|
-11.02
|
-11.89
|
-12.89
|
-13.96
|
Net income
1 |
-9.671
|
-6.903
|
-6.838
|
-7.725
|
-5.833
|
-6.536
|
-6.501
|
-8.563
|
-8.408
|
-11.02
|
-11.89
|
-12.89
|
-13.96
|
Net margin
|
-5,933.13%
|
-4,234.97%
|
-42,737.5%
|
-7,882.65%
|
-6,013.4%
|
-
|
-14,132.61%
|
-19,913.95%
|
-30,028.57%
|
-78,750%
|
-254,625.27%
|
-276,059.96%
|
-298,922.27%
|
EPS
2 |
-0.5500
|
-0.3900
|
-0.3800
|
-0.4300
|
-0.3200
|
-0.3600
|
-0.3600
|
-0.4800
|
-0.4700
|
-0.6100
|
-0.6300
|
-0.6667
|
-0.7200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/5/22
|
8/3/22
|
11/2/22
|
3/2/23
|
5/3/23
|
8/7/23
|
11/1/23
|
3/28/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-44.2
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
15
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
8,287.29%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
10.11
USD Average target price
19.67
USD Spread / Average Target +94.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.57% | 200M | | +10.30% | 118B | | +10.33% | 106B | | -11.00% | 23.4B | | -1.80% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -14.72% | 15.97B | | +6.41% | 14.03B | | +14.80% | 11.67B |
Bio Therapeutic Drugs
|